MGNXMacroGenics, Inc.
The schedule
- Thu15Oct
Regulatory feedback on MacroGenics’ lead program’s path to a pivotal study will clarify the required trial size, endpoints, and timeline, influencing how investors value the pipeline at a $3.44 stock price.
- Wed11Nov
MacroGenics is expected to provide a mid-2026 clinical update on a lead immuno-oncology bispecific program, a binary catalyst that could re-rate the stock sharply from $3.44 in either direction.
- Sat15May
Q3 2026 results and an initial look at 2027 development spending will indicate how aggressively MacroGenics plans to fund late-stage trials, influencing dilution risk around a $3.44 share price.
- Sun15Aug
Full-year 2026 results and year-end cash disclosure will frame MacroGenics’ strategic options for 2027, including partnering, pipeline prioritization, or additional financing, from a starting point of $3.44.
Past
- Thu13Aug
Actual outcome: Bull
MacroGenics met EPS estimates and reported a narrower year-over-year loss, despite revenue lagging expectations. The stock's bullish trajectory toward the $4.10 target was driven by the company's announcement of a streamlined operating model and strengthened financial position, which was further bolstered by a $10 million milestone payment from Gilead Sciences for licensing a preclinical bispecific program.
Q2 2026 earnings will highlight how sustainable the recent revenue acceleration is and whether collaboration and milestone income can offset ongoing R&D-driven losses at a $3.44 share price.
- Mon15Jun
Actual outcome: Bull · $4.32 at outcome
MacroGenics announced it will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA approval of TZIELD. This significant non-dilutive cash injection alleviated immediate liquidity concerns and reduced the near-term risk of a dilutive equity financing. Consequently, the stock rallied well past its bull target as investors priced in the improved balance sheet outlook.
With leverage rising and cash balances trending lower, MacroGenics may opportunistically tap the equity market around mid-2026 via a secondary or ATM program while the stock trades near $3.44.
- Wed13May
Actual outcome: Bull · $4.01 at outcome
Stock rose 12.2% from event to outcome date, aligning with the bull trajectory.
Q1 2026 results and management’s updated cash runway commentary will test whether the recent revenue growth and positive operating cash flow can be sustained, with the stock near its 52-week high at $3.44.
